Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2018 Dec 6;132(23):2422-2424.
doi: 10.1182/blood-2018-10-879650.

DUO delivers for duvelisib

Jennifer R Brown  1
Affiliations
Comment

DUO delivers for duvelisib

Jennifer R Brown. Blood. .

Abstract

In this issue of Blood, Flinn et al report the final results of the phase 3 registration trial DUO, which compared the novel PI3Kδ,γ inhibitor duvelisib with ofatumumab in patients with relapsed refractory chronic lymphocytic leukemia (CLL) and demonstrated a significant improvement in progression-free survival (PFS) with duvelisib. On 24 September 2018, these results led to US Food and Drug Administration (FDA) approval of duvelisib for the therapy of CLL patients after ≥2 prior regimens.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: J.R.B. has consulted for Verastem Oncology, Gilead Sciences, TG Therapeutics, Janssen, Pharmacyclics, AbbVie, Genentech, Acerta Pharma, AstraZeneca, BeiGene, Loxo Oncology, Sunesis Pharmaceuticals, Sun Pharma, Pfizer, Celgene, Kite Pharma, Redx Pharma, and Astellas Pharma; has received an honorarium from Teva Pharmaceutical Industries and research funding from Verastem Oncology, Gilead Sciences, Sun Pharma, and Loxo Oncology; and has served on Data Safety Monitoring Boards for MorphoSys and Invectys.

Figures

None
Progression-free survival in DUO per investigator assessment, comparing duvelisib with ofatumumab. BID, twice a day; DUV, duvelisib; OFA, ofatumumab. See the complete Figure 1 in the article by Flinn et al that begins on page 2446.
See this image and copyright information in PMC

Comment on

  • The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
    Flinn IW, Hillmen P, Montillo M, Nagy Z, Illés Á, Etienne G, Delgado J, Kuss BJ, Tam CS, Gasztonyi Z, Offner F, Lunin S, Bosch F, Davids MS, Lamanna N, Jaeger U, Ghia P, Cymbalista F, Portell CA, Skarbnik AP, Cashen AF, Weaver DT, Kelly VM, Turnbull B, Stilgenbauer S. Flinn IW, et al. Blood. 2018 Dec 6;132(23):2446-2455. doi: 10.1182/blood-2018-05-850461. Epub 2018 Oct 4. Blood. 2018. PMID: 30287523 Free PMC article. Clinical Trial.

References

    1. Flinn IW, Hillmen P, Montillo M, et al. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL. Blood. 2018;132(23):2446-2455. - PMC - PubMed
    1. Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma. J Clin Oncol. 2017;35(35):3898-3905. - PubMed
    1. Kaneda MM, Messer KS, Ralainirina N, et al. PI3Kγ is a molecular switch that controls immune suppression [Published correction appears in Nature. 2017;542(7639):124]. Nature. 2016;539(7629):437-442. - PMC - PubMed
    1. Weaver D, Sprott K, Pachter J, et al. Duvelisib inhibition of chemokines in patients with CLL (DUO study) and iNHL (DYNAMO study). J Clin Oncol. 2018;36(suppl 15):12048.
    1. O’Brien S, Patel M, Kahl BS, et al. Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. Am J Hematol. 2018;93(11):1318-1326. - PMC - PubMed